Sietse Jonkman serves as vice president of portfolio management at Paragon Biosciences. He focuses on driving strategic and operational initiatives and investment diligence for Paragon portfolio companies.

Prior to joining Paragon, Dr. Jonkman served as executive director, global program leader at Sarepta Therapeutics, where he led cross-functional teams in advancing siRNA and gene therapy programs for neuroscience and neuromuscular indications. In a previous role at Sarepta, he was responsible for leading annual corporate planning initiatives, conducting portfolio valuation analyses, and providing strategic leadership for the company’s Duchenne muscular dystrophy (DMD) asset portfolio.

Earlier in his career, Dr. Jonkman worked as a consultant at Boston Consulting Group (BCG), where he developed comprehensive valuation models and provided strategic recommendations for biotech and pharmaceutical clients across multiple therapeutic areas.

Dr. Jonkman holds a Ph.D. in Biology from the University of Cambridge.